Percheron Therapeutics Ltd

Company Profile

• Business description

  Percheron Therapeutics Ltd is a clinical-stage biotechnology company advancing first-in-class immuno-oncology therapies to tackle some of the difficult-to-treat cancers. The company's product pipeline comprises the following drug candidates: avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor, and HMBD-002, a monoclonal antibody that has shown activity in a wide range of animal models of cancer and has shown evidence of synergy when combined with other immuno-oncology drugs such as Keytruda (pembrolizumab). Its operating segments are ATL1102, which generates maximum income, and HMBD-002.

• Contact

  35 Collins Street
  Level 30, Collins Place
  MelbourneVIC3000
  AUS

  T: +61 398278999

  https://www.percherontx.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Drug Manufacturers - Specialty & Generic

  Fiscal Year End

  Employees

  8